Transcriptomic profiles of cervical cancer under TL and L-OHP combination therapy

OverviewThis repository contains the processed bulk RNA-sequencing and single-cell RNA-sequencing (scRNA-seq) data supporting the findings of our study, which demonstrates that Triptolide (TL) enhances Oxaliplatin (L-OHP)-induced immunogenic cell death (ICD) via the ROS-ER stress pathway and reshapes the tumor immune landscape in cervical cancer.Data Files Included1. Single-cell RNA-sequencing (scRNA-seq) DataFile Name: adata_post_UMAP_Leiden.h5adBiological Model: C57BL/6 mice bearing TC-1 cervical cancer surrogate tumors.Experimental Design: Tumors were harvested at the study endpoint (Day 28) and dissociated into single-cell suspensions for sequencing via the 10x Genomics platform.Treatment Groups: The dataset comprises 4 distinct treatment groups (n=3 biological replicates per group for sequencing): Vehicle Control, L-OHP monotherapy, TL monotherapy, and TL+L-OHP combination therapy.Data Content: The provided .h5ad file includes the post-QC gene-cell expression matrices, dimensionality reduction coordinates (PCA/UMAP), and clustering metadata used for downstream analyses.2. Bulk RNA-sequencing DataFile Name: normalized_counts.csvExperimental Design: Transcriptomic profiling to investigate the comprehensive transcriptional changes in oxidative stress-related and ER stress-related genes following TL treatment.Treatment Groups: Includes data from the Control group and TL treatment group (4 biological replicates each, labeled as Control_1-4 and TL_1-4).